Dr Shamsi will explore the evolution of oncology imaging, the limitations of RECIST 1.1, and how additional measurements can enhance early-phase decision-making and late-phase efficacy confirmation in clinical trials.
- The evolution of oncology clinical trials since RECIST 1.1
- The impact of immunotherapies, cell therapies, cancer vaccines, and ADCs
- RECIST Plus – enhanced features that integrate volumetric and radiological parameters for a more comprehensive analysis